Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis
- Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals
- New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in patients with atrial fibrillation, including recurrent bleeding events
- Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice